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THERE IS considerable controversy re- garding the recurrence of thromboembolic episodes following discontinuation of long-term anticoagulant therapy. Most reports from this country1-9 (table 1), claim a high incidence of thromboembolism after cessation of long-term anticoagulants. This is in striking contrast to what has been reported in some European studies.'0 12 The question of a rebound state of hypercoaaulability, especially after gastrointestinal bleeding necessitating stopping of anticoagulants, has been commented upon both in clinical and experimental studies.3 5 9 13 16 Others have considered that the reported increase in thromboembolism is due to the natural history of the underlying disease when the "protection" from anticoagulants has been removed. '7 The clinical studies supporting No autopsies were performed on two patients. One of these patients died suddenly at home, and one died suddenly in the hospital. These were presumed to be coronary deaths.
Coumadin was stopped in 14 patients after an episode of gastrointestinal, genitourinary, or other bleeding. Two of this group died (14 per cent). These were all placed in group II. Discussion This is the first reported study of a group of patients who were followed after long-term anticoagulation was stopped without specific indication (in 120 of 134). Most previous studies have been a tabulation of a retrospective collection of cases of those who have abandoned an anticoagulant program or in whom anticoagulants had to be stopped beCirculation, Volune XXXII, Decemnber 1965 cause of some contraindication to therapy. It is possible such selection may inject bias.
There was only one episode of thrombosis during the first 6 weeks after discontinuing coumadin in 134 patients. There was no notable difference among patients who had their coumadin stopped abruptly or gradually. These results suggest that there is no "rebound" hypercoagulability in respect to clinical thromboembolism following abrupt or gradual discontinuation of long-term coumadin therapy.
An increased risk of thrombosis after discontinuation of anticoagulation therapy following a bleeding episode has been noted by Sise et al.9 Of the 14 patients in this study in whom coumadin was stopped during a bleeding episode, two died. In contrast to Sise's study, no thrombotic episodes occurred during the first 6 weeks following cessation of therapy. One of these patients died suddenly during treatment of a recurrence of massive gastrointestinal bleeding. Several months previously he had had anticoagulation therapy stopped because of gastrointestinal bleeding.
Summary
Long-term anticoagulant therapy (coumadin) was gradually tapered over a 6-week period in 63 patients, and stopped abruptly in 71. All of these patients had been on coumadin following myocardial infarction. A VAN CLEVE careful follow-up showed that there was no difference in the incidence of thrombotic events in the first 6 weeks after discontinuation of therapy, whether this was stopped abruptly or gradually. These results suggest that clinically recognized "rebound" thrombosis does not occur after long-term coumadin therapy is stopped. There appears to be no hazard inherent in stopping long-term coumadin therapy abruptly. A possible exception to this is patients whose therapy must be stopped because of bleeding episodes.
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